Carregant...

The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells

Inhibitors of PARP1 are approved therapeutic agents in ovarian carcinomas. We determined whether the novel clinically relevant CHK1 inhibitor SRA737 interacted with PARP1 inhibitors to kill carcinoma cells. In multiple mammary and ovarian cancer lines SRA737 synergized with the PARP1 inhibitors olap...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Biol Ther
Autors principals: Booth, Laurence, Roberts, Jane, Poklepovic, Andrew, Dent, Paul
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6154848/
https://ncbi.nlm.nih.gov/pubmed/30024813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1472189
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!